September 21, 2014
September 20, 2014
September 19, 2014
World’s First Stem-Cell Drug Approval Achieved in Canada
On May 17, 2012, Osiris Therapeutics announced that Canadian health regulators approved Prochymal, its drug for acute graft-versus host disease in children who have failed to respond to steroid treatment. Prochymal is the first stem cell drug to be approved anywhere in the world for a systemic disease.
Graft-versus-host disease, a potentially fatal complication from bone marrow transplant, involves the newly implanted cells attacking the patient’s body. Until now, there have been no approved treatments for the disease. Prochymal is designed to control inflammation and promote tissue regeneration. Since the drug is made up of bone marrow stem cells derived from an adult donor, it circumvents ethical concerns that are raised by the use of stem cells derived from embryos.
The Canadian approval is contingent on Osiris conducting further post-market testing—and it’s anticipated that if the FDA approves the drug when marketing authorization is sought later this year, similar conditions would be imposed.
<span class="advertise"> Advertisement </span>
- Court Rejects FDA’s Interpretation of the Statute’s Device Definition as “Erroneous and Unreasonable”
- 340B Federal Drug Pricing Program September Update: Self-Disclosures
- Judge Requires PhRMA To Initiate New 340B Orphan Drug Lawsuit to Challenge Interpretive Rule
- Looking Towards the Future of Pharmaceuticals in Africa
- National Institute of Standards and Technology (NIST) Issues Draft Report Enumerating Risks and Protections to Consider When Evaluating Mobile Apps for Your Enterprise
- FDA Focuses on Sex-Specific Data in Medical Device Clinical Trials